EUROPEAN ASSOCIATION OF HAEMOPHILIA AND ALLIED D..

19th Annual EAHAD Congress

 

3-6 February 2026 Dublin
Close
N. Poster
Poster title
Applicant name
Status
  3-PT ´Long-term survival of total hip and total knee arthroplasty in people with haemophilia´ Gijs Aertssen Received Received
  3-PO UK NEQAS BC survey outcome of the laboratory measurement of Altuvoct (efanesoctocog alfa) samples using an in vitro-spiked product specific calibrator. Anna Williams Received Received
  3-NUR Impact of New Hemophilia Therapies on Therapeutic Patient Education: A Survey of French Nurses Nicolas Guerin Received Received
  4-NUR A Nurse-Led Multidisciplinary Approach to post-infusion Gene Therapy Management Deirdre Gorman Received Received
  4-PO Assessing FVIII:C Assay Discordance in Hemophilia A Carriers: A Retrospective Study Highlighting the Value of Combined One-Stage and Chromogenic Assays Claire Flaujac Received Received
  7-PO rFVIII–Platelet Interactions Promote Fibrin Network Densification in Hemophilia A Clots Gillian Patman Received Received
  10-PO Bridging the Assay Gap: One more reagent for Accurate Measurement of Efanesoctocog Alfa Angelo Claudio Molinari Received Received
  17-PO Clinical Validation of Chromogenic Substrate Assay as a Novel Coagulation Test for Evaluating Coagulation Function in Hemophilia A patients without Inhibitor During Treatment with Emicizumab Masato Bingo Received Received
  29-PO Factor VIII Regulates Angiogenesis and Promotes Endothelial Barrier Stability Gillian Patman Received Received
  30-PO Factor VIII Regulates Angiogenesis and Vessel Stability Via Extracellular Matrix Proteins Gillian Patman Received Received
  32-PO Assessing the real-world value of hemophilia care: how suitable are patient-centered outcomes for comparing hospital value? Diaz Prameyllawati Received Received
  34-PO In Vivo Assessment of the Procoagulant Effects of Recombinant Factor IX Concentrates During Emicizumab Therapy in a Hemophilia A Mouse Model NORA Butta Coll Received Received
  38-PO Comparison of extravascular distribution between three extended half-life factor IX (EHL-FIX) concentrates utilising physiology-based pharmacokinetic (PBPK) modelling Sjoerd Koopman Received Received
  39-PO Immune Tolerance Induction in Haemophilia A Patients with Inhibitors: Updated Analysis from MOTIVATE Gillian Patman Received Received
  47-PO Non-Joint Bleeds in Patients With Haemophilia A or B Without Inhibitors: Results From the Concizumab Phase 3 explorer8 Study Victor Jiménez Yuste Received Received
  55-PO Concizumab efficacy in haemophilia A/B in an intra-patient comparison vs previous prophylaxis (phase 3 explorer8 study): Post-hoc sensitivity analysis Hermann Eichler Received Received
  56-PO Early start of emicizumab in infants with severe haemophilia A, a three year follow up Saad Ahmed Received Received
  58-PO Assessment of joint health and patient-physician alignment on joint damage reports in a cohort of people with haemophilia A: real-world Insights from the CHESS III Study Claudia Mighiu Received Received
  67-PO The WFH Guidelines for the Management of Haemophilia: AAV Gene Therapy, 2025 Donna Coffin Received Received
  68-PO Evolution of joint health and physical activity in people with haemophilia A without factor VIII inhibitors switching to emicizumab prophylaxis: 12-month interim analysis of the BEYOND ABR study Helen Miller Received Received
  78-PO Intracranial haemorrhage in children with inherited bleeding disorders- A single centre review Melanie Bladen Received Received
  81-PO Postoperative Knee Stiffness Following Total Knee Arthroplasty (TKA) in Patients with Hemophilia (PWH): A Single-Centre Review Konstantinos Kaoullas Received Received
  83-PO Concizumab Plasma Concentration Measurements and Modelling for Personalised Dose Adjustment in Patients with Haemophilia A/B with and without Inhibitors Johnny Mahlangu Received Received
  86-PO Total knee and hip arthroplasty in haemophilic arthropathy: medium-term experience from a national comprehensive care centre. Nicolaas Kotze Received Received
  90-PO From Research to Reality; Setting up a Gene Therapy Hub for Haemophilia Patients in Ireland Margaret Nolan Received Received
  98-PO HEMOPHILIA A AND ANTITHROMBIN DEFICIENCY: A CASE OF NATURAL HEMOSTATIC REBALANCING Lorenzo Torrieri Received Received
  106-PO Real world outcomes comparing Factor VIII and Emicizumab in boys with Severe Haemophilia A Rebecca Ling Received Received
  108-PO Early indicators of cardiovascular risk in paediatric patients with haemophilia: results from 24-hour blood pressure monitoring Natalia Pasikowska Received Received
  116-PO Adults Hemophilia A patients with unmet clinical needs: How fast can we close the gap in South America in the 21st century? Maria Ferrer Received Received
  119-PO Real-world efficacy and safety of concizumab in patients with haemophilia B with inhibitors from the Early Access Program in France Alexandre Butelet Received Received
  124-PO EXPERIENCE IN THE DIAGNOSIS AND PROPHYLAXIS OF SEVERE HEMOPHILIA A DUE TO A DE NOVO MUTATION IN A SINGLE CENTER Carmen Gil Barroso Received Received
  128-PO Analysis of Bone Density in People with Haemophilia: A single centre comparison of Severity Levels Stephanie Taylor Received Received
  147-PO Disease Burden and Unmet Medical Need in Severe Hemophilia in Greece: Insights from Clinicians and Patients. Nikoletta Sofiaki Received Received
  149-PO Late Diagnosis and Management of Pregnancy in a Patient with Platelet-Type von Willebrand Disease: A Case Report Claire Flaujac Received Received
  153-PO First surgical experience with efanesoctocog alfa in a 9-month-old Previously Untreated Patient with Severe Hemophilia A on emicizumab prophylaxis benjamin GILLET Received Received
  155-PO Hip joint bleeds in boys with Haemophilia – A single centre review. Nicola Hubert Received Received
  156-PO Case Analysis of Marstacimab Subcutaneous Injection for Prophylactic Treatment in Hemophilia Patients from China´s Pilot Zone Jing Dai Received Received
  162-PO Experience and feelings of patients with haemophilia A treated with efanesoctocog alfa in four centres in the Grand-Est region of France Alexandre Butelet Received Received
  166-PO Implementing therapeutic drug monitoring for low emicizumab levels due to hypoalbuminemia: a case report Amber de Vos Received Received
  167-PO EMICIZUMAB USE IN CHILDREN AND ADULTS WITH HEMOPHILIA A MULTICENTER REPORT IN A MIDDLE-INCOME COUNTRY ARGENTINA RICCHERI CECILIA Received Received
  170-PO Influence of Body Mass on prophylaxis dose and consumption of Efanesoctocog alfa Benedict McCarthy Received Received
  176-PO Enhancing Understanding of Gene Editing in Hemophilia: A New WFH Education Initiative Mayss Naccache Received Received
  178-PO TOTAL KNEE ARTHROPLASTY (TKA) IN PATIENTS WITH HEMOPHILIA (PWH) Styliani Christidi Received Received
  179-PO Impact of Emicizumab Treatment on Patients with Severe Hemophilia A: A Retrospective Descriptive Study in Chile (REDEEM) Alegna Rada Received Received
  185-PO BENEFITS OF A MULTIDISCIPLINARY CONSULTATION IN HEMOPHILIC PATIENTS: EXPERIENCE FROM A SECONDARY CARE HOSPITAL Carmen Gil Barroso Received Received
  194-PO The first UK case report of successful haemodialysis in a person with severe haemophilia B receiving extended half-life factor IX prophylaxis Natasha Wetherall Received Received
  200-PO Clinical Evaluation of Emicizumab in Patients with Hemophilia A: Experience from Our Center. Ana Felicidad de las Nieves Received Received
  203-PO Establishing an Efficient Clinical Trial Ecosystem for Hemophilia Gene Therapy Mahmoud Abu-Riash Received Received
  206-PO Macrophage-LRP1 involvement in VWF clearance: an in-silico analysis of the interactions between physiological and pathological VWF variants with LRP1. Monica Sacco Received Received
  215-PO Pharmacokinetic-Pharmacodynamic Modelling of Von Willebrand Factor/Factor VIII Prophylaxis in Von Willebrand Disease Jelien den Hollander Received Received
  216-PO Psychosocial factors worsened by bleeding in VWD: the VWD360 study Kate Khair Received Received
  218-PO Beyond Extreme Thrombocytosis: Rethinking Risk Factors for Acquired von Willebrand Syndrome in Ph-Negative MPN Uros Markovic Received Received
  219-PO Clinical Outcomes of 1:1 pdVWF/FVIII Prophylaxis in Children Under 6 Years With Severe VWD: Results from the WIL-33 Study Gillian Patman Received Received
  221-PO Perioperative von Willebrand factor and factor VIII kinetics in surgical von Willebrand disease patients treated with different clotting factor concentrates Zoë Gras Received Received
  222-PO Identifying the challenges posed by living with VWD: the VWD360 study Kate Khair Received Received
  223-PO Prophylaxis with 1:1 pdVWF/FVIII concentrate provides cost savings compared to on-demand treatment in type 3 VWD patients with severe bleeding: A United States payer and societal perspective Gillian Patman Received Received
  224-PO Successful treatment with emicizumab in acquired von Willebrand disease in a 13-year-old child: a case report Amber de Vos Received Received
  227-PO Validation of a new pharmacokinetic population model for perioperative dosing of a highly purified plasma-derived von Willebrand factor (pdVWF): the WIL-PKPOP-CHIR study Marie-Hélène ANDRE-BONNET Received Received
  228-PO Global Disparities in von Willebrand Disease Diagnosis and Management: An analysis using the WFH World Bleeding Disorders Registry Donna Coffin Received Received
  232-PO Comparative Cost Analysis of Prophylaxis with 1:1 Ratio pdVWF/FVIII Concentrate vs rVWF in Type 3 von Willebrand Disease Adults in the United States Gillian Patman Received Received
  234-PO Red-Lilly App: Evaluation of the menstrual cycle in every woman Susan Halimeh Received Received
  240-PO Assessing Awareness and Knowledge of Bleeding Disorders in Girls and Women- Insights from a Cross-Sectional Survey at Ruhr University Bochum June Schwarzbach Received Received
  243-PO Management of the preconception phase, pregnancy, and childbirth in women with Glanzmann thrombasthenia: findings from the European Association of Haemophila and Allied Disorders survey Karlijn Rutten Received Received
  246-PO Living with Factor VII deficiency: data from the FVIID 360 study Kate Khair Received Received
  247-PO Treatment of Type 1 Plasminogen Deficiency in Women and Girls with Reproductive Tract Lesions: Pharmacokinetics and Clinical Outcomes with IV Plasminogen Replacement Therapy Karen Thibaudeau Received Received
  248-PO Identifying predictors of disease burden in women with bleeding disorders: analyses from the Cinderella study Kate Khair Received Received
  250-PO Evaluation of Fibrinolysis Testing Methods in Haemostasis and Thrombosis Laboratories: Results of a National Survey by the Spanish Society on Thrombosis and Haemostasis (SETH) Laboratory Working Group NORA Butta Coll Received Received
  251-PO Safety of intramuscular vaccinations in children with inherited platelet disorders Annick Moor Received Received
  254-PO Correlation between FXIII genotype, residual activity, and female bleeding phenotype with emphasis on hypermenorrhea and pregnancy loss Rosa Sonja Alesci Received Received
  256-PO Genetic Screening Alters Diagnosis and Management in Patients with ITP Eva Zetterberg Received Received
  259-PO Is It Safe to Use DDAVP in Children Under 6 Years with Bleeding Disorders? A Systematic Review Dennise Tontoh Received Received
  263-PO Pregnancy in mild-moderate factor VII deficiency: A case series Nuria Bermejo Received Received
  270-PO Surveillance of patients with Hermansky-Pudlak syndrome at risk of pulmonary fibrosis Janine Collins Received Received
  273-PO Retrospective analysis of F13A1 and F13B gene variants and their impact on laboratory parameters and symptoms Carsten Detering Received Received
  274-PO Clinical and genetic characterization of combined Factor V and Factor II deficiency: insights into genotype–phenotype correlation Rosa Sonja Alesci Received Received
  276-PO Severe Congenital Factor VII Deficiency Without Molecular Diagnosis: The Case for Comprehensive Genomic Analysis PANAGIOTIS CHRISTOFOROU Received Received
  294-PO Approaches across the spectrum in congenital factor X deficiency: real-world lessons from a 31-Year Single-Centrer experience. Saverio Pancetti Received Received
  298-PO Acquired von Willebrand Syndrome in a Patient with IgM Multiple Myeloma and Waldenström Macroglobulinemia: A Complex Hemostatic Challenge Agata Ogloza Puchowska Received Received
  302-PO Navigating Acquired Hemophilia A: A Six-Year Regional Study from Italy´s Liguria Angelo Claudio Molinari Received Received
  304-PO Familial factor V deficiency. An undocumented mutation. Fernando Vazquez Lagos Received Received
  305-PO Pharmacokinetics of Coagadex® in Patients with Acquired Factor X Deficiency Associated with AL Amyloidosis Undergoing Elective Surgery Mirella Calcinai Received Received
  311-PO Case series of severe FXIII deficiency in pregnancy Emily Millen Received Received
  312-PO Optimising care for People with Bleeding Disorders (PBD): Development of an Integrated Haemostasis Pain Clinic Niamh Larkin Received Received
  315-PO Implementation and evaluation of questionnaires to Review Problematic Menstrual Bleeding and Its Impact on Quality of Life. Janet Cleary Received Received
  316-PO The Weight of Trust: Emotional Barriers to Shared Decision-Making in Haemophilia Scott McLean Received Received
  320-PO Development of a Product Switch Clinical Pathway for an en-masse switch to Efanesoctocog Alfa Prophylaxis Niamh Larkin Received Received
  324-PO ´Predicting recovery after joint bleeding in persons with bleeding disorders´ Gijs Aertssen Received Received
  333-PO Clinical, Psychosocial, Quality of Life Outcomes and Patient-Physician Discrepancies in Joint Damage Reporting in a cohort of People with Haemophilia A: real-world insights from the CHESS III Study Claudia Mighiu Received Received
  335-PO Exploring Psychological and Identity Factors Influencing Health Care Engagement Among Canadian Women With Bleeding Disorders: Preliminary Findings on PTSD, Anxiety, Resilience, and Self-Compassion Julia Hews-Girard Received Received
  340-PO A glance back as we move forward: The shifting paradigm of paediatric psychological care in haemophilia – a review of referrals to a paediatric psychology service over a decade. Yvonne Duane Received Received
  349-PO Home delivery for medication specialising in the treatment of haemophilia and other coagulopathies in Madrid, Spain Lourdes Pérez Received Received
Tel.: +34 91 736 2385
LOCAL TIME
Contact: Katarina Gluic
Hours: Mon-Thu 8:30-17:00 Fri 8:30-15:00
23:19
For help with a poster, please specify the poster number, the first author and the congress and we will reply shortly.
Poster no.
Contact name
E-mail
Telephone
Congress
Comments

 

19th Annual EAHAD Congress

 

3-6 February 2026 Dublin
FAQs
Virtual Poster Gallery
Search and consult posters online
in an exclusive section
for each poster
    ACTIVE FROM 03/02/2026 TO 03/02/2026
Poster
Gallery
Upload
Poster
Featured Poster
Vote poster
Poster Discussion
Forum
                  




PosterSessionOnline
Logo Draft
 
Logo Cert